Protagonist Therapeutics, Inc (PTGX) Stock Price & Analysis
Protagonist Therapeutics, Inc (PTGX) rose 8.00% to USD 105.87 as of June 10, 2026 at 02:27 UTC, according to Nexqual real-time market data.
PTGX last closed at USD 98.03; the session ranged USD 98.08–106.48 on volume of 861,847 shares. Market capitalization is $6.81B, with a 52-week range of USD 49.38–107.84 (NGM). Source: Nexqual, June 10, 2026 at 02:27 UTC.
Key Statistics (as of June 10, 2026 at 02:27 UTC)
| Price | USD 105.87 |
|---|---|
| Change | ▲ 8.00% (up) |
| Previous Close | USD 98.03 |
| Open | USD 98.5 |
| Day Range | USD 98.08 – 106.48 |
| 52-Week Range | USD 49.38 – 107.84 |
| Volume | 861,847 shares |
| Market Cap | $6.81B |
| Exchange | NGM |
Technical Analysis (PTGX)
Nexqual's technical model rates PTGX "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 02:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.08 (neutral) |
| vs SMA50 | Above (USD 101.28) |
| MACD | -0.23 (negative) |
Analyst Ratings (PTGX)
Wall Street analysts rate PTGX "Strong Buy" based on 13 analysts, with a mean price target of USD 118.69 (range USD 100–137), per Nexqual as of June 10, 2026 at 02:27 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 118.69 |
| High Target | USD 137 |
| Low Target | USD 100 |
| Buy / Hold / Sell | 12 / 1 / 0 |
Earnings (PTGX)
| Next Earnings Date | 2026-05-05 |
|---|---|
| EPS Estimate | USD 1.77 |
| Revenue Estimate | $211.32M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.05 vs est -0.65 ▲ beat |
| 2025-12-31 | USD -0.69 vs est -0.54 ▼ miss |
| 2025-09-30 | USD -0.62 vs est -0.64 ▲ beat |
| 2025-06-30 | USD -0.55 vs est -0.52 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Financials & Fundamentals (PTGX)
| Total Revenue | $74.06M |
|---|---|
| Revenue Growth (YoY) | +99.00% |
| Gross Margin | +100.00% |
| Operating Margin | -6.47% |
| Profit Margin | -154.88% |
| ROE | -17.06% |
| Debt / Equity | 1.49 |
| Current Ratio | 17.76 |
| Total Cash | $547.79M |
| Total Debt | $9.78M |
| Free Cash Flow | $-77.66M |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Financial Health Score (PTGX)
Nexqual rates Protagonist Therapeutics, Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:27 UTC.
| Growth | Critical — Revenue -89% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $548M cash vs $10M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$78M, burning cash |
| Efficiency | Critical — ROE -17%, ROA -12.4% |
Ownership (PTGX)
| Insider Ownership | +0.71% |
|---|---|
| Institutional Ownership | +125.27% |
| Shares Outstanding | 64.31M |
| Float | 52.49M |
| Short % of Float | +13.40% |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Leadership (PTGX)
Protagonist Therapeutics, Inc is led by Dinesh V. Patel (age 68), CEO, President, Secretary & Director, per Nexqual as of June 10, 2026 at 02:27 UTC.
| CEO, President, Secretary & Director | Dinesh V. Patel (age 68) |
|---|---|
| Executive VP & CFO | Asif Ali (age 51) |
| Executive VP, Chief Scientific Officer | Newman Yeilding |
| Executive Vice President of Business Development | Carter J. King (age 54) |
Major Backers & Investors (PTGX)
Notable institutional backers of Protagonist Therapeutics, Inc include Farallon Capital Management LLC, UBS Group AG, RTW Investments LP, according to Nexqual as of June 10, 2026 at 02:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Farallon Capital Management LLC | 9.87% |
| UBS Group AG | 8.05% |
| RTW Investments LP | 7.87% |
| Wellington Management | 5.6% |
| Janus Henderson Group PLC | 4.5% |
| Johnson & Johnson | 3.81% |
| T. Rowe Price | 1.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 22.91% |
| Vanguard Group | 19.18% |
| State Street | 6.38% |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
From Protagonist Therapeutics, Inc's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
- It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SNDX | Syndax Pharmaceuticals, Inc. | USD 17.69 | ▲ 2.02% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.86 | ▲ 1.69% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| XENE | Xenon Pharmaceuticals Inc. | USD 52.79 | ▲ 2.05% |
| SRRK | Scholar Rock Holding Corporatio | USD 45.58 | ▲ 2.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:27 UTC. This page is informational and not investment advice.